SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.50-1.3%Jan 16 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: david james who wrote (1154)6/1/2000 3:50:00 PM
From: Biomaven  Read Replies (1) of 52153
 
I agree with david on the issue of who is doing the trading here. The fact that the more significant move was on the Phase III data means that it is likely not the company insiders that are trading but rather those associated with the large trials - whether doctors, patients, CRO's or whoever else.

This issue is compounded by the little-discussed fact that some so-called double blind trials aren't really double blind at all, because there's some side effect that reveals which is the real stuff - skin turns green or whatever.

For a less-jaundiced view ("it's just the smart money") see Rick's post on this:

Message 13805281

Be interesting to read the full text of the article if anyone finds it somewhere on the web.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News